NASDAQ:VRNA - Nasdaq - US9250501064 - ADR - Currency: USD
NASDAQ:VRNA (5/29/2025, 10:42:01 AM)
74.925
+0.99 (+1.35%)
The current stock price of VRNA is 74.925 USD. In the past month the price increased by 0.98%. In the past year, price increased by 512.51%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 52.58 | 685.67B | ||
JNJ | JOHNSON & JOHNSON | 15.26 | 369.07B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 19.25 | 305.30B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.48 | 221.20B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 16.04 | 218.84B | ||
MRK | MERCK & CO. INC. | 9.8 | 191.79B | ||
PFE | PFIZER INC | 7.28 | 132.78B | ||
SNY | SANOFI-ADR | 11.87 | 127.38B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.47 | 96.66B | ||
GSK | GSK PLC-SPON ADR | 8.93 | 80.24B | ||
ZTS | ZOETIS INC | 27.66 | 74.13B | ||
HLN | HALEON PLC-ADR | 23.14 | 51.07B |
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. The company is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The firm's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The firm's wholly owned subsidiary is Verona Pharma, Inc.
VERONA PHARMA PLC - ADR
Riverside, 3 More London Place
London SE1 2RE GB
CEO: David Zaccardelli
Employees: 209
Phone: 442032834200
The current stock price of VRNA is 74.925 USD. The price increased by 1.35% in the last trading session.
The exchange symbol of VERONA PHARMA PLC - ADR is VRNA and it is listed on the Nasdaq exchange.
VRNA stock is listed on the Nasdaq exchange.
17 analysts have analysed VRNA and the average price target is 92.36 USD. This implies a price increase of 23.27% is expected in the next year compared to the current price of 74.925. Check the VERONA PHARMA PLC - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
VERONA PHARMA PLC - ADR (VRNA) has a market capitalization of 6.37B USD. This makes VRNA a Mid Cap stock.
VERONA PHARMA PLC - ADR (VRNA) currently has 209 employees.
VERONA PHARMA PLC - ADR (VRNA) has a support level at 68.03. Check the full technical report for a detailed analysis of VRNA support and resistance levels.
The Revenue of VERONA PHARMA PLC - ADR (VRNA) is expected to grow by 987.32% in the next year. Check the estimates tab for more information on the VRNA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
VRNA does not pay a dividend.
VERONA PHARMA PLC - ADR (VRNA) will report earnings on 2025-08-06.
VERONA PHARMA PLC - ADR (VRNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2).
The outstanding short interest for VERONA PHARMA PLC - ADR (VRNA) is 17.66% of its float. Check the ownership tab for more information on the VRNA short interest.
ChartMill assigns a technical rating of 10 / 10 to VRNA. When comparing the yearly performance of all stocks, VRNA is one of the better performing stocks in the market, outperforming 99.38% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to VRNA. The financial health of VRNA is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months VRNA reported a non-GAAP Earnings per Share(EPS) of -2. The EPS decreased by -163.16% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -31.17% | ||
ROE | -72.35% | ||
Debt/Equity | 1.07 |
ChartMill assigns a Buy % Consensus number of 85% to VRNA. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of 114.83% and a revenue growth 987.32% for VRNA